Evidence map›Paper›PMID 42385193›Full record

ArticleMicrobiologyOpen2026

Emergence of Ceftazidime-Avibactam-Induced KPC Variants (KPC-25/127) in Intracranial Infection and Implications for Clinical Management.

Ke Lei, Ying Tian, Chaoliang Xiong, Jing Lei, Dong Chen, Xiangni Bai, Mohd H Abdul-Aziz, Jiao Xie, Zeshi Liu

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in MicrobiologyOpen, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ke LeiDepartment of Clinical Laboratory, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Ying TianDepartment of Clinical Laboratory, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Chaoliang XiongDepartment of Clinical Laboratory, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Jing LeiDepartment of Clinical Laboratory, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Dong ChenDepartment of Clinical Laboratory, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Xiangni BaiDepartment of Clinical Laboratory, XD Group Hospital, Xi'an, China.
Mohd H Abdul-AzizUniversity of Queensland Centre for Clinical Research (UQCCR), Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.
Jiao XieDepartment of Pharmacy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.ORCID 0000-0002-7115-829X
Zeshi LiuDepartment of Clinical Laboratory, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Funding

Key Research and Development Plan of Shaanxi Province 2024SF-YBXM-160
6 · The paper itself

Abstract

The emergence of novel Klebsiella pneumoniae carbapenemase (KPC) variants contributing to clinical treatment failure poses a substantial threat to public health. To inform the clinical management of infections caused by KPC-variant-harboring K. pneumoniae, this study reports the complex evolutionary trajectory of ceftazidime-avibactam (CAZ-AVI)-resistant KPC-variant-harboring K. pneumoniae in a single patient during CAZ-AVI treatment. Three KPC-producing K. pneumoniae (KPC-KP) isolates were obtained from a patient with K. pneumoniae infection who received sequential treatment with imipenem followed by CAZ-AVI. Isolate K2, harboring bla

Indexed as

Anti-Bacterial AgentsAzabicyclo CompoundsBacterial Proteinsbeta-LactamasesCeftazidimeKlebsiella InfectionsKlebsiella pneumoniaeDrug CombinationsDrug Resistance, Multiple, BacterialHumansImipenemMicrobial Sensitivity TestsThird Generation CephalosporinsAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsBacterial Proteinsbeta-LactamasescarbapenemaseCeftazidimeDrug CombinationsImipenemThird Generation Cephalosporinsceftazidime‐avibactamKlebsiella pneumoniaeKPC‐127KPC‐25

Identifiers

PMID42385193
PMCPMC13322651

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.